The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.
The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) ...
CERo Therapeutics received FDA approval for its IND CMC amendment, crucial for starting CER-1236 patient dosing. The phase 1 trial will assess CER-1236's safety and efficacy in relapsed or refractory ...
The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients ages 1 year and older with acute myeloid leukemia ...
Medications for AML include chemotherapy and newer targeted therapies. With several options available, the right medication for you will depend on the specific characteristics of your cancer. Acute ...
Findings showed the hazard ratio for OS compared with busulfan was 0.67 in all randomized patients. The Food and Drug Administration (FDA) has approved Grafapex ™ (treosulfan) for injection with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback